About 11,108 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  2,953 results

The value of SPARCC sacroiliac MRI scoring in axial psoriatic arthritis and its associa...
International Journal of Rheumatic Diseases; Gezer HH, Duruöz MT

Jan 27th, 2022 - This study aimed to assess patients with axial psoriatic arthritis (AxPsA) using the Canadian Spondyloarthritis Research Consortium (SPARCC) sacroiliac joint (SIJ) scores and to seek correlations between magnetic resonance imaging (MRI) scores and...

Polychondritis in a Patient With Ankylosing Spondylitis on an Anti-TNF-α Biosimilar Agent.
Journal of Clinical Rheumatology : Practical Reports on R... Duro T, Li S et. al.

Jan 26th, 2022 - Polychondritis in a Patient With Ankylosing Spondylitis on an Anti-TNF-α Biosimilar Agent.|2022|Duro T,Li S,Jose D,Khawar T,|

Bone Involvement in Patients with Spondyloarthropathies.
https://doi.org/10.1007/s00223-021-00933-1 10.1136/annrheumdis-2013-203425 10.1016/j.berh.2010.01.005 10.1002/art.41667
Calcified Tissue International; Lems W, Miceli-Richard C et. al.

Jan 24th, 2022 - Spondyloarthropathies (SpA) are common systemic inflammatory rheumatic diseases, in which, as in other rheumatic diseases, levels of markers of bone resorption are elevated, leading to bone loss and elevated risk of vertebral fractures. However, t...

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  772 results see all →

Clinicaltrials.gov  133 results

The Effects of Tele-Yoga in Ankylosing Spondylitis Patients

Jan 19th, 2022 - Yoga is an ancient discipline that emerged in India thousands of years ago, designed to bring balance and health to the physical, mental, emotional and spiritual dimensions of the individual.Due to its therapeutic effects, yoga can be considered a...

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Jan 11th, 2022 - This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability ov...

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ...

Jan 5th, 2022 - The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) a...

A Study to Assess Disease Activity in Adult Participants With Ankylosing Spondylitis Who Receive Upadacitinib in a Real-world Setting

Dec 20th, 2021 - Axial spondyloarthritis (axSpA), which encompasses radiographic axSpA (r-axSpA, also known as ankylosing spondylitis [AS]) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chroni...

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Dec 14th, 2021 - The purpose of this study is to demonstrate the impact of secukinumab on progression of structural damage in the spine, as measured by the mSASSS in patients with AS.

see more →

News  564 results

Trial Data Confirm Heightened Risks With JAK Inhibitor

Jan 26th, 2022 - It's official: full data from a randomized trial evaluating safety of the oral JAK inhibitor tofacitinib (Xeljanz), approved for treating rheumatoid arthritis and related disorders as well as ulcerative colitis, are now published -- and they are n...

Tofacitinib Approved for New Ankylosing Spondylitis Indication

Dec 16th, 2021 - The US Food and Drug Administration (FDA) approved a supplemental new drug application for tofacitinib (Xeljanz, Xeljanz XR) that adds active ankylosing spondylitis in adults to its list of indications, according to a December 14 announcement from...

Upadacitinib (Rinvoq) Gains Psoriatic Arthritis as Second FDA-Approved Indication

Dec 15th, 2021 - The US Food and Drug Administration has approved a 15-mg extended release tablet of upadacitinib (Rinvoq) for adults with psoriatic arthritis who had an inadequate response or intolerance to one or more anti-tumor necrosis factor drugs, manufactur...

Peripheral manifestations make mark on spondyloarthritis trajectory
Heidi Splete

Dec 7th, 2021 - Peripheral manifestations contribute significantly to disease activity in adults with spondyloarthritis (SpA), point toward a generally worse prognosis, and play a big role in defining the phenotypic clustering of the heterogenous disease, accordi.

Peripheral Manifestations Influence Spondyloarthritis Trajectory

Dec 7th, 2021 - Peripheral manifestations contribute significantly to disease activity in adults with spondyloarthritis (SpA), point toward a generally worse prognosis, and play a big role in defining the phenotypic clustering of the heterogenous disease, accordi...

see more →

Patient Education  10 results see all →